Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial
出版年份 2018 全文链接
标题
Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial
作者
关键词
Chronic myeloproliferative disorders, JAK inhibitor, Polycythemia vera, Ruxolitinib
出版物
ANNALS OF HEMATOLOGY
Volume -, Issue -, Pages -
出版商
Springer Nature
发表日期
2018-05-27
DOI
10.1007/s00277-018-3365-y
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study
- (2017) Francesco Passamonti et al. LANCET ONCOLOGY
- Myeloproliferative Neoplasms
- (2017) Jerry L. Spivak NEW ENGLAND JOURNAL OF MEDICINE
- From leeches to personalized medicine: evolving concepts in the management of polycythemia vera
- (2016) Alessandro M. Vannucchi HAEMATOLOGICA
- Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial
- (2016) S. Verstovsek et al. HAEMATOLOGICA
- Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease
- (2016) Holly Geyer et al. JOURNAL OF CLINICAL ONCOLOGY
- The potential role of hematocrit control on symptom burden among polycythemia vera patients: Insights from the CYTO-PV and MPN-SAF patient cohorts
- (2016) Robyn Marie Scherber et al. LEUKEMIA & LYMPHOMA
- How We Identify and Manage Patients with Inadequately Controlled Polycythemia Vera
- (2016) Andreas Reiter et al. Current Hematologic Malignancy Reports
- From leeches to personalized medicine: evolving concepts in the management of polycythemia vera
- (2016) Alessandro M. Vannucchi HAEMATOLOGICA
- Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial
- (2016) S. Verstovsek et al. HAEMATOLOGICA
- Frequency and prognostic value of resistance/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera
- (2015) Alberto Alvarez-Larrán et al. BRITISH JOURNAL OF HAEMATOLOGY
- Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera
- (2015) NEW ENGLAND JOURNAL OF MEDICINE
- How I treat polycythemia vera
- (2014) A. M. Vannucchi BLOOD
- Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project
- (2013) G. Barosi et al. BLOOD
- Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study
- (2013) A Tefferi et al. LEUKEMIA
- Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN
- (2012) Elisabetta Antonioli et al. AMERICAN JOURNAL OF HEMATOLOGY
- Cardiovascular Events and Intensity of Treatment in Polycythemia Vera
- (2012) Roberto Marchioli et al. NEW ENGLAND JOURNAL OF MEDICINE
- Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera
- (2011) A. Alvarez-Larran et al. BLOOD
- Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet
- (2011) Tiziano Barbui et al. JOURNAL OF CLINICAL ONCOLOGY
- The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
- (2009) J. W. Vardiman et al. BLOOD
- A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis
- (2008) F. Passamonti et al. BLOOD
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started